C4 Therapeutics (NASDAQ:CCCC), a biotechnology company focused on developing novel treatments, is making waves in the oncology space with its lead drug candidate CFT1946. This... BMO Capital ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Darout covers the Healthcare sector, focusing on stocks such as C4 Therapeutics, AstraZeneca, and Terns Pharmaceuticals. In another report released today, JMP Securities also maintained a Buy rating ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), boosting the price target to $134.00.

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Monday. The brokerage set a “hold” rating on the stock.